Your GeneSight report arrived with medications sorted into green, yellow, and red categories. These color codes indicate potential gene-drug interactions based on how your body metabolizes medications and how drugs interact with your brain receptors—but they don’t predict whether a medication will work for you or guarantee you’ll avoid side effects. For background on the research supporting how these results are generated, see our post on the benefits of GeneSight for medication management.
Understanding the Three Color Categories
Green medications labeled “use as directed” show no predicted gene-drug interactions based on the genes analyzed. This doesn’t mean these medications will definitely work well or not cause side effects—it means your genetic profile doesn’t suggest obvious pharmacokinetic or pharmacodynamic complications. You can take these medications at standard doses without genetic factors requiring special consideration.
Yellow medications indicate “moderate gene-drug interaction.” Your genetic variants suggest these medications might require dose adjustments, more careful monitoring, or consideration of how they’re metabolized compared to standard prescribing. Yellow doesn’t mean avoid these medications—it means discuss genetic findings with your psychiatrist before prescribing or when adjusting doses.
Red medications signal “significant gene-drug interaction.” Your genetic profile suggests these medications may pose challenges related to metabolism, receptor binding, or other genetic factors that could affect safety or efficacy. However, red doesn’t mean a medication is wrong for you. Some people respond well to red-category medications when prescribed with appropriate dose adjustments and monitoring.
The report focuses on identifying medications more likely to cause problems, not identifying the medication that will work best. This distinction matters because it shapes realistic expectations. GeneSight testing helps rule out potentially problematic options rather than pointing to the perfect medication. Your psychiatrist integrates genetic information with your symptom profile, medical history, and previous medication responses to guide treatment decisions (Greden et al., 2019).
How Pharmacokinetic Results Affect Prescribing
Pharmacokinetic genes influence how quickly your body metabolizes medications. The GeneSight test evaluates genes like CYP2D6 and CYP2C19—liver enzymes that process many psychiatric medications. These genes have multiple variants that determine whether you’re an ultra-rapid metabolizer, normal metabolizer, intermediate metabolizer, or poor metabolizer.
If you’re an ultra-rapid metabolizer for a particular enzyme, you clear medications processed by that enzyme very quickly. Standard doses might not work because the medication doesn’t stay in your system long enough to produce therapeutic effects. Your psychiatrist might prescribe higher doses or choose medications processed through different pathways. Understanding your metabolizer status explains why medications that help others at standard doses haven’t worked for you.
Poor metabolizers process medications slowly, causing standard doses to accumulate in the body. This can increase side effect risk even at doses that are therapeutic for most people. Your psychiatrist might prescribe lower doses, monitor more carefully for side effects, or select medications metabolized through pathways less affected by your genetic variants.
The combinatorial algorithm used by GeneSight weighs multiple genetic variants together rather than looking at single genes in isolation. Research shows this weighted multi-gene approach better predicts medication blood levels and clinical outcomes than single-gene testing (Tesfamicael et al., 2024). Your report reflects complex interactions between multiple genes affecting how medications behave in your system.
Pharmacodynamic Results and Brain Chemistry
Pharmacodynamic genes affect how medications interact with receptors in your brain. GeneSight evaluates genes like HTR2A (serotonin receptor) and SLC6A4 (serotonin transporter)—proteins that influence how neurotransmitters work. Variants in these genes may affect medication response or side effect vulnerability in ways distinct from metabolism.
For example, certain SLC6A4 variants are associated with different responses to SSRIs. While the evidence remains somewhat mixed and these genetic markers don’t reliably predict individual outcomes, they provide additional information your psychiatrist considers alongside other factors. Pharmacodynamic information tends to be less definitive than pharmacokinetic data but still contributes to the complete picture.
The report might show that a medication flagged yellow or red due to receptor genetics could still work well if taken at appropriate doses with careful monitoring. The goal isn’t avoiding these medications entirely but understanding they may require more individualized dosing or closer attention to response and side effects than medications with no predicted genetic complications.
Catalyst Psychiatry’s board-certified psychiatrists integrate GeneSight results into comprehensive medication management. With over 20 years of combined experience, the team understands how to apply genetic information appropriately—using it to inform rather than dictate treatment decisions for patients throughout Corvallis and the mid-Willamette Valley.
What Your Results Don’t Tell You
GeneSight can’t predict treatment success. The test identifies genetic factors that might complicate medication use but doesn’t guarantee medications will work or that you’ll avoid side effects. Two people with identical genetic profiles may have completely different treatment outcomes based on factors like stress levels, sleep quality, medical conditions, social support, and individual brain chemistry variations not captured by the genes tested.
The report doesn’t diagnose mental health conditions or determine what disorder you have. It doesn’t test for depression risk, identify OCD likelihood, or predict anxiety severity. GeneSight serves as one tool within comprehensive psychiatric evaluation and treatment—a source of information about medication processing and receptor function, not a complete guide to mental health treatment.
Results don’t explain why you’re depressed or what caused your anxiety. The genes evaluated affect medication response, not disorder etiology. Understanding this distinction prevents misinterpreting genetic testing as identifying “the cause” of your mental health condition. Most psychiatric disorders arise from complex interactions between many genes, environmental factors, and life experiences—far beyond what medication-response testing assesses.
Your results remain stable throughout your life because your genetic code doesn’t change. However, scientific understanding of gene-drug interactions continues evolving. Your psychiatrist may reinterpret results as new research emerges without requiring additional testing. What we know about specific genetic variants and their clinical significance improves continuously as more people undergo testing and researchers track outcomes.
Using Results in Medication Selection
When starting a new medication, your psychiatrist reviews your GeneSight results to identify potential complications before prescribing. If several medications might work for your symptoms, genetic information helps choose among options. A green-category medication might be preferred over a red-category option if both target your symptoms similarly—though clinical factors sometimes outweigh genetic considerations.
If you’ve already tried medications before testing, your results help explain past experiences. Did you have minimal side effects from green-category medications but couldn’t tolerate red-category drugs? Genetic factors might explain these patterns. Did green medications not work while a red medication helped? This suggests your treatment response depends more on non-genetic factors or that you’re an exception to the genetic predictions.
When a medication flagged yellow or red appears to be the best clinical option despite genetic concerns, your psychiatrist can prescribe it with appropriate precautions. This might mean starting at lower doses, increasing more gradually, monitoring more frequently, or checking medication blood levels to ensure therapeutic dosing. Genetic information guides cautious use rather than automatic avoidance.
Your GeneSight results complement other information your psychiatrist considers: your symptom profile, previous medication responses, medical conditions, concurrent medications, and personal preferences. Genetic testing represents one data point among many. Treatment decisions should never rely solely on genetic results while ignoring clinical presentation and individual circumstances.
Discussing Results With Your Psychiatrist
Your appointment to review GeneSight results should cover what the color categories mean for your specific situation. Ask your psychiatrist which genetic variants showed up in your testing and what they suggest about medication processing. Understanding your metabolizer status for key enzymes helps you grasp why certain medications might work differently for you than for others.
Discuss medications you’ve tried previously in relation to your genetic results. Do patterns emerge that help explain past experiences? If you struggled with a medication your results flag as problematic, genetic factors might have contributed. If you did well on a red-category medication, your individual response superseded genetic predictions—valuable information for future prescribing.
Ask whether your results suggest trying medications you haven’t used yet. If you’ve primarily tried medications your genetics flag as potentially problematic, switching to green-category options might improve outcomes. Conversely, if you’ve already tried green options without success, genetic factors probably aren’t the main issue limiting treatment response.
The board-certified psychiatrists at Catalyst Psychiatry review GeneSight results thoroughly with patients, explaining what genetic findings mean for medication selection and how to use this information alongside clinical assessment. The practice serves patients throughout Corvallis and the mid-Willamette Valley who need expert guidance interpreting pharmacogenomic testing. View our full range of psychiatric services to understand how genetic testing fits into our care model.
When Genetic Guidance Differs From Clinical Judgment
Sometimes the best medication for your clinical presentation appears in the red category on your GeneSight report. Your psychiatrist may recommend it anyway if clinical benefits likely outweigh genetic concerns. This represents appropriate use of genetic information—considering it while not letting it override sound clinical judgment based on decades of treatment research and experience.
Conversely, a green-category medication might not work despite favorable genetics. GeneSight tests 14 genes, but hundreds of genes influence medication response. The ones tested explain only part of the picture. Non-genetic factors like inflammation, hormone levels, sleep patterns, and stress all affect treatment outcomes independent of the genes GeneSight evaluates.
Research supports using GeneSight to inform prescribing, but studies show modest effect sizes. The GUIDED trial found significantly better outcomes when doctors received genetic results, but differences weren’t dramatic—22.5% remission with GeneSight-guided treatment versus 7.6% without (Greden et al., 2019). This suggests genetic information helps but doesn’t revolutionize outcomes for most people.
Your psychiatrist weighs genetic information against clinical factors, adjusting relative importance based on your situation. If you’re medication-naive with no previous treatment attempts, genetic guidance carries more weight. If you have extensive medication history clearly showing what does and doesn’t work, clinical track record often trumps genetic predictions.
What to Do If Results Seem Unhelpful
If most medications you need appear in yellow or red categories, don’t panic. Many people with challenging genetic profiles respond well to medications their GeneSight results flag as potentially problematic. The key is prescribing with genetic factors in mind—careful dose selection, gradual increases, close monitoring—rather than avoiding these medications entirely.
If your results don’t clarify why previous medications failed, genetic factors probably aren’t the main issue. Other considerations like inadequate dosing, insufficient treatment duration, inaccurate diagnosis, or comorbid conditions might better explain poor responses. Your psychiatrist can investigate these alternative explanations and adjust your treatment approach accordingly.
Sometimes genetic testing reveals you’re an ultra-rapid or poor metabolizer for enzymes processing most psychiatric medications. This explains treatment difficulties but doesn’t automatically solve them. Your psychiatrist needs to prescribe creatively, potentially using medications metabolized through pathways less affected by your genetic variants or employing non-medication treatments like psychotherapy or brain stimulation.
Results showing few genetic complications don’t guarantee treatment success. If you have favorable genetics but medications still haven’t worked adequately, this suggests factors beyond pharmacogenetics limit your response. Your psychiatrist might explore advanced treatment options like Deep TMS or SPRAVATO®—approaches working through mechanisms different from oral medications where genetic variants affecting traditional antidepressants become less relevant.
FAQ Section
Q: Can I share my GeneSight results with multiple doctors?
A: Yes, your results belong to you. You can request copies to share with other healthcare providers. Since results don’t change over time, one test serves for all future prescribing needs with any provider.
Q: What if a medication in my green category didn’t work?
A: Green indicates no predicted gene-drug interaction—not guaranteed effectiveness. Many factors beyond genetics influence medication response. Your psychiatrist considers genetic results alongside clinical factors when selecting alternatives.
Q: Should I stop taking a medication that appears in my red category?
A: Never stop psychiatric medications without consulting your prescriber. Red indicates potential complications but doesn’t mean a medication is wrong for you, especially if it’s working. Discuss concerns with your psychiatrist before making changes.
Q: How often should I retake the GeneSight test?
A: Once is sufficient. Your genetic code doesn’t change, so results remain valid throughout your life. Scientific interpretation may evolve, but you don’t need repeat testing.
Q: Will my insurance cover medication changes based on GeneSight results?
A: Insurance covers medications regardless of GeneSight results. The question is whether they’ll cover GeneSight testing itself, which varies by plan. Once you have results, they don’t affect medication coverage decisions.
Conclusion
GeneSight results provide information about potential gene-drug interactions affecting medication metabolism and brain receptor function, helping your psychiatrist make more informed prescribing decisions. Understanding that genetic testing identifies potentially problematic medications rather than predicting treatment success helps set appropriate expectations. The most effective use of GeneSight involves integrating genetic findings with your complete clinical picture, medication history, and personal treatment goals.
To discuss your GeneSight results and develop a personalized medication management plan, the board-certified psychiatrists at Catalyst Psychiatry can help you understand what your genetic information means for your treatment options. Call 541-730-4400 or contact us online to schedule an appointment.
References
- Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, K., Gilbert, A., Burns, L., Jablonski, M. R., & DeChairo, B. (2019). Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research, 111, 59–67. https://pubmed.ncbi.nlm.nih.gov/30677585/
- Myriad Genetics/GeneSight. (2022). Understanding the GeneSight test algorithm. https://genesight.com/genetic-insights/understanding-the-genesight-test-algorithm/
- Tesfamicael, K., O’Shea, R., Burns, T., Scott, R., & Liu, C. C. (2024). The utility of pharmacogenomics in the management of depression: An umbrella review and updated meta-analysis. Frontiers in Psychiatry, 15, 1276410. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1276410/full